Navigation Links
Oxygen Biotherapeutics, Inc. Enrolls First Patient in Traumatic Brain Injury Clinical Trial in Switzerland
Date:12/4/2009

DURHAM, N.C., Dec. 4 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBT) today announced that the first patient has been enrolled in the company's Phase II-b, dose escalation, clinical trial in Switzerland for use of Oxycyte(TM) emulsion in traumatic brain injury (TBI). Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier.

"This trial is of invaluable importance in improving the outcome of patients with severe TBI. We hope to finally prove that there is a safe and effective treatment for this devastating injury," said Chris Stern, company chairman and CEO. "I know that our shareholders have been wondering why it has taken so long to dose the first patient. It has taken longer than expected due to important training and logistical considerations at the trial sites. Those are being resolved on a site-by-site basis and enrollment should now start progressing. I'll go into more detail on that in my blog over the weekend. But I have to emphasize that our main criterion in the trial is safety. We therefore intentionally did not rush enrollment in the early stage. Our early competitors showed us how dangerous it is to rush a trial. We will not do that."

Out of respect for the privacy of the patients and their families, the company will not be disclosing any identifying information about patients in the study or the type of accident that caused the TBI.

The company has named the 128 patient study "Safety and Tolerability of Oxycyte in Patients with Traumatic Brain Injury" or "STOP TBI". Since study participants will all be emergency cases, it is not possible to predict the precise timing of the flow of patients into the study, which is being supervised by a contract research organization, PFC Pharma Focus AG. The principal investigator is Dr. Michael Reinert of the Department of Neurosurgery at the University Hospital of Berne.

The dose escalation studies will focus on finding the lowest dose of Oxycyte that provides clinical benefit in traumatic brain injury while minimizing adverse effects. Dose levels of Oxycyte will start at 1.0 ml/kg body weight and escalate in steps to 2.0 ml/kg, and 3.0 ml/kg for subsequent patient cohorts. Escalation of dose will only occur after a favorable review of safety data by an independent Data Safety Monitoring Board.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine(TM). The company has developed a perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product (Oxycyte(TM)) and has out-licensed an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs as well as medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetes wounds and ulcers, and cosmetic applications which are being marketed under the Dermacyte name. More information is available at www.oxybiomed.com.

SOURCE Oxygen Biotherapeutics, Inc.


'/>"/>
SOURCE Oxygen Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Medical Oxygen Systems - Global Market Opportunities
2. Oxygen Biotherapeutics, Inc. Begins Shipping Cosmetic Product to Customers
3. Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009
4. Oxygen Biotherapeutics, Inc. to Webcast Shareholder Meeting
5. Oxygen Biotherapeutics, Inc. Receives Phase II Trial Approval in Israel
6. Oxygen Biotherapeutics, Inc. Submits Milestone Achievement Notice to Vatea Fund
7. New NIH-Funded Study Shows Masimo Rainbow SET(R) May Help Clinicians Assess Oxygenation in Children With Sickle Cell Disease
8. Oxygen Biotherapeutics, Inc. Receives Letter From FDA Outlining Path Forward to Resume Oxycyte Clinical Trials in TBI in U.S.A.
9. Battelle Scientists Named on Patent for Making Oxygen From Light and Water
10. Northfield Laboratories Inc. Presentation at FDA/NIH Workshop on Hemoglobin-Based Oxygen Carriers
11. Oxygen Relieves IBS and Constipation Symptoms in New Clinical Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... YORK , December 2, 2016 ... Braces & Support) is Expected to Gain a Significant Market ... to Orthopedic Ailments  ... , According to ... Study on Medical Implants Sterile Packaging: Clamshell Product Type Segment ...
(Date:12/2/2016)... On Thursday, the NASDAQ Composite and ... the Dow Jones Industrial Average managed to stay in green. ... which prompted Stock-callers this morning to look at the performances ... NUVA ), Smith & Nephew PLC (NYSE: SNN ... Cesca Therapeutics Inc. (NASDAQ: KOOL ). You can ...
(Date:12/2/2016)... -- The concept of rare diseases and the idea that ... has been taking shape in Europe ... initiatives related to orphan medicinal products have been emerging at ... states individually. Many member states in the EU have led ... medicinal products, the result of which took the shape of ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... The annual time frame to change Medicare health ... is ending December 7th. Currently-enrolled Medicare beneficiaries who are looking to switch from their ... D) need to make changes during this period order for their new policy to ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... More than ... and while 84 percent of parents report speaking with their child about sex related ... sexually transmitted diseases. , Mediaplanet is proud to announce the launch of its second ...
(Date:12/2/2016)... ... December 02, 2016 , ... Sourced from the Isbre Springs beneath the 5,000 ... unmatched natural purity of just 6 ppm TDS (Total Dissolved Solids) in addition to ... been available in several ShopRite and FoodTown stores in NJ and received rave comments ...
(Date:12/2/2016)... Miami, FL (PRWEB) , ... December 02, 2016 ... ... over 5,100 hot meals to needy individuals and families from eight different sites ... Florida on Thanksgiving Day. Over 1,000 volunteers worked very hard on Thanksgiving morning ...
(Date:11/30/2016)... , ... November 30, 2016 , ... ... they now offer a comprehensive in-house dental plan for all patients. Understanding that ... a plan that gives patients a number of perks, including discounts on many ...
Breaking Medicine News(10 mins):